Thursday 7 May, 2026
Introduction: Gut-targeted compounds present an opportunity to locally affect the gastrointestinal (GI) tract while simultaneously benefitting from a more desirable…
Read morePoster: Drug/Disease Modelling - Absorption & PBPK
DEVELOPMENT OF A PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL OF AN ANTI-HER2 ANTIBODY-DRUG CONJUGUATE WITH REZETECAN PAYLOAD IN MICE
Thursday 7 May, 2026
Introduction A quantitative understanding of the whole-body pharmacokinetics (PK) of antibody-drug conjugates (ADCs) is essential for establishing the exposure-response relationship…
Read moreAssessing Cross-Version Simcyp Simulator Prediction Performance Using a Bioequivalence Framework to Support EMA Qualification
Thursday 7 May, 2026
Introduction: The Simcyp Simulator V19 was qualified for predicting drug-drug interactions for 6 CYP enzymes (CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6,…
Read morePHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL FOR PREDICTING FOOD EFFECT ON THE PHARMACOKINETICS OF RADOTINIB
Thursday 7 May, 2026
Objectives: Radotinib, a weakly basic and lipophilic second-generation tyrosine kinase inhibitor, was approved for the treatment of chronic myeloid leukemia…
Read morePHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING OF ANTIDEPRESSANTS: A SCOPING REVIEW OF EXISTING MODELS, APPLICATIONS, AND SOFTWARE TOOLS
Thursday 7 May, 2026
Introduction and Objectives: Major depressive disorder affects an estimated 5.7% of the global adult population and represents a substantial contributor…
Read moreDEVELOPMENT OF A GENERAL PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL OF DRUG DISTRIBUTION AFTER PERIOCULAR ADMINISTRATION
Thursday 7 May, 2026
Introduction: Periocular injections represent an alternative route for ocular drug delivery, offering potential advantages in terms of efficacy, safety, and…
Read moreMODEL-INFORMED DRUG DEVELOPMENT FOR IBREXAFUNGERP IN ACUTE VULVOVAGINAL CANDIDIASIS: APPLICATION OF PBPK AND EXPOSURE–RESPONSE MODELING TO SUPPORT DRUG SUBSTANCE MANUFACTURING CHANGES
Thursday 7 May, 2026
Objectives: Ibrexafungerp is a triterpenoid antifungal agent approved in the US in adult and post-menarchal pediatric females for the treatment…
Read moreA Whole-Body PBPK Model to Quantify Organ-Specific Biodistribution and Systemic Clearance of Bacteriophages
Thursday 7 May, 2026
Background and Objectives: Bacteriophages (phages) are viruses that selectively infect bacteria and are under renewed investigation as therapeutic agents against…
Read moreCharacterization and comparison of absorption profiles between three novel sustained-release formulations of oral flucytosine for cryptococcal meningitis treatment through population pharmacokinetic modeling
Thursday 7 May, 2026
Objectives: Cryptococcal meningitis (CM) is a fungal infection of the central nervous system characterized by inflammation of the meninges. It…
Read moreValidation and refinement of the large molecule biodistribution model in PK-Sim.
Thursday 7 May, 2026
Background: The predictive performance of the PK-Sim large molecule biodistribution model has been publicly evaluated on a dataset from 8…
Read more